Lantern Pharma announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184. The company plans to further develop and validate the assay for its use as a potential tool for patient selection in later stage clinical trials across a broad range of solid tumors that have shown sensitivity to LP-184. In a key publication on the utility and value of biomarkers in oncology trials among some of the most common cancers, titled Does biomarker use in oncology improve clinical trial failure risk?

A large-scale analysis by Parker,et al., 2021 in Cancer Medicine found success of clinical trials to be significantly correlated to the incorporation of biomarkers. The hazard ratio analysis of the Markov biomarker models examined how likely clinical trial success was associated with biomarker use versus no biomarker use. Hazard ratios indicated that for biomarker-based drugs clinical trial success was largest for breast cancer (12-fold) followed by melanoma (eightfold) and lung cancer (sevenfold).

The data provide the most extensive look at biomarker use to date in oncology, with an advanced statistical method. findings indicate that biomarkers provide a statistically significant benefit, despite the fact study includes biomarkers not yet FDA approved. By incorporating the PTGR1 biomarker into LP-184's development strategy, Lantern Pharma is aligning with best practices in precision medicine and aiming to increase the likelihood of successful clinical outcomes in future clinical trials.

Lantern Pharma plans to implement this assay in upcoming clinical trials for LP-184, potentially streamlining the development process and increasing the likelihood of successful outcomes. LP-184-- a novel therapeutic in clinical development for the potential treatment of malignant gliomas, pancreatic cancer, and atypical teratoid rhabdoid tumors (ATRT)-- has also been granted an Orphan Drug Designation by the FDA, along with a Rare Pediatric Disease Designation. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, have accelerated the development of growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program.

On average, newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. These forward-looking statements include, among other things, statements relating to: future events or future financial performance; the potential advantages of RADR®?

platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; strategic plans to advance the development of drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and estimates regarding clinical trial timing & patient enrollment; research and development efforts of internal drug discovery programs and the utilization of RADR®? platform to streamline the drug development process; intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for the drug candidates and to maximize their commercial potential by advancing such drug candidates or in collaboration with others. There are a number of important factors that could cause the actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that the risk that its research and the research of collaborators may not be successful, the risk that promising observations in preclinical studies do not ensure that later studies and development will be successful, the risk that they may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (iv) the risk that none of their product candidates has received FDA approval.